<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>AI News Aggregator - Full Text</title><link>https://Tairon861.github.io/ai-news-aggregator/feed.xml</link><description>Recent AI News with Full Content</description><atom:link href="https://Tairon861.github.io/ai-news-aggregator/feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 28 Nov 2025 12:45:44 +0000</lastBuildDate><item><title>Google DeepMind (Google DeepMind)</title><link>https://deepmind.com/blog/feed/basic/</link><description>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://lh3.googleusercontent.com/9pd-ekE9IkXLNhoDGTFIrrP_ADecW6W00EYibC_f0RARMQ6oB2hIubzUWn_b0CThN5NjoFkxrE3eamY7eEeN-mT0cVV5k2XNxHAgFZuEdQ=w1200-h630-n-nu" /&gt;&lt;/div&gt;
    
      
      
      
      
        
        
          
          
          
          
          
          
          
          
        
        
        
        
        
          
        
        
        
        
        
        
          
        
        
        
        
          
        
        
        
          
        
        
        
        
        
          
        
      
    
    
      Google DeepMind
    
    
      &lt;!-- Google Tag Manager --&gt;
      
      &lt;!-- End Google Tag Manager --&gt;
    
    
      
    
    
      
    
    
      
    
    
      
    
    
      
    
    
    
    
    
    
    
    
    
      
    
    
    
    
      
    
  
    
    
    
    
    
      



  
    
    
  


  



    
    
      
  
    




  
    



  


  
    




  
    



  


  
    &lt;hr class="divider" /&gt;

  
    




  &lt;section class="grid section-default spacer-block-md-bottom section-padding-top " id="news"&gt;
    &lt;div class="grid__inner grid__column--span-12"&gt;
      
        
      
      
        

&lt;div class="news-group-section container spacer-block-none-bottom"&gt;
  
    &lt;div class="news-group__wrapper grid"&gt;
      
      &lt;div class="news-group__featured-wrapper featured-column grid__column--span-4-xs grid__column--span-4-sm grid__column--span-8-md grid__column--span-6-lg"&gt;
        &lt;div class="news-group__featured-inner"&gt;
          
            &lt;div class="feature-wrapper active"&gt;
              



&lt;article class="card card-blog card--large_text_media"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-4 card__title"&gt;Introducing Nano Banana Pro&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

            &lt;/div&gt;
          
        &lt;/div&gt;
      &lt;/div&gt;

      
      &lt;div class="news-group__article-wrapper article-column grid__column--span-4-xs grid__column--span-4-sm grid__column--span-4-md grid__column--span-6-lg"&gt;
        
          
            
            


  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;AlphaFold: Five years of impact&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Revealing a key protein behind heart disease&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Breeding healthier and stronger honeybees&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Start building with Gemini 3&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;How we’re bringing AI image verification to the Gemini app&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Build with Nano Banana Pro, our Gemini 3 Pro Image model&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  



          
        
      &lt;/div&gt;
    &lt;/div&gt;
  
&lt;/div&gt;

      
    &lt;/div&gt;
  &lt;/section&gt;</description><content:encoded>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://lh3.googleusercontent.com/9pd-ekE9IkXLNhoDGTFIrrP_ADecW6W00EYibC_f0RARMQ6oB2hIubzUWn_b0CThN5NjoFkxrE3eamY7eEeN-mT0cVV5k2XNxHAgFZuEdQ=w1200-h630-n-nu" /&gt;&lt;/div&gt;
    
      
      
      
      
        
        
          
          
          
          
          
          
          
          
        
        
        
        
        
          
        
        
        
        
        
        
          
        
        
        
        
          
        
        
        
          
        
        
        
        
        
          
        
      
    
    
      Google DeepMind
    
    
      &lt;!-- Google Tag Manager --&gt;
      
      &lt;!-- End Google Tag Manager --&gt;
    
    
      
    
    
      
    
    
      
    
    
      
    
    
      
    
    
    
    
    
    
    
    
    
      
    
    
    
    
      
    
  
    
    
    
    
    
      



  
    
    
  


  



    
    
      
  
    




  
    



  


  
    




  
    



  


  
    &lt;hr class="divider" /&gt;

  
    




  &lt;section class="grid section-default spacer-block-md-bottom section-padding-top " id="news"&gt;
    &lt;div class="grid__inner grid__column--span-12"&gt;
      
        
      
      
        

&lt;div class="news-group-section container spacer-block-none-bottom"&gt;
  
    &lt;div class="news-group__wrapper grid"&gt;
      
      &lt;div class="news-group__featured-wrapper featured-column grid__column--span-4-xs grid__column--span-4-sm grid__column--span-8-md grid__column--span-6-lg"&gt;
        &lt;div class="news-group__featured-inner"&gt;
          
            &lt;div class="feature-wrapper active"&gt;
              



&lt;article class="card card-blog card--large_text_media"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-4 card__title"&gt;Introducing Nano Banana Pro&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

            &lt;/div&gt;
          
        &lt;/div&gt;
      &lt;/div&gt;

      
      &lt;div class="news-group__article-wrapper article-column grid__column--span-4-xs grid__column--span-4-sm grid__column--span-4-md grid__column--span-6-lg"&gt;
        
          
            
            


  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;AlphaFold: Five years of impact&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Revealing a key protein behind heart disease&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Breeding healthier and stronger honeybees&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Start building with Gemini 3&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;How we’re bringing AI image verification to the Gemini app&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  
    &lt;div class="grid__column--span-4-xs "&gt;
      



&lt;article class="card card-blog card--small_h"&gt;
  &lt;div class="card__inner"&gt;
    &lt;div class="card__content"&gt;
      &lt;h3 class="heading-6 card__title"&gt;Build with Nano Banana Pro, our Gemini 3 Pro Image model&lt;/h3&gt;
      



    &lt;/div&gt;
    
      
        
  
    
    
    
  


      
    
  &lt;/div&gt;
&lt;/article&gt;

    &lt;/div&gt;
  



          
        
      &lt;/div&gt;
    &lt;/div&gt;
  
&lt;/div&gt;

      
    &lt;/div&gt;
  &lt;/section&gt;</content:encoded><guid isPermaLink="false">https://deepmind.com/blog/feed/basic/</guid></item><item><title>[NEW] What we still don’t know about weight-loss drugs (MIT Technology Review)</title><link>https://www.technologyreview.com/2025/11/28/1128511/what-we-still-dont-know-about-weight-loss-drugs/</link><description>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://wp.technologyreview.com/wp-content/uploads/2025/11/glp1-pregnancy.jpg?resize=1200,600" /&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="class"&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 chronoton/executive-summary_0"&gt;&lt;div class="chronotonExecutiveSummary__summaryContainer--3bc10da0658ecd8e2ef22c6023461fb5"&gt;&lt;button class="chronotonExecutiveSummary__toggleButton--1cd6118db37e8a8252fc4cd8bbadcb85" type="button"&gt;&lt;span class="chronotonExecutiveSummary__toggleText--a713e14989fe65c5162db2b69cb422c9"&gt;EXECUTIVE SUMMARY&lt;/span&gt;&lt;svg class="chronotonExecutiveSummary__toggleArrow--a8c1be9c06a9f066a767b3af80d859a1" fill="none" height="7" viewBox="0 0 11 7" width="11" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M1 1L5.5 5.5L10 1" stroke="#58C0B3" stroke-linecap="round" stroke-width="1.5"&gt;&lt;/svg&gt;&lt;/button&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_1 html_first"&gt; &lt;p&gt;&lt;strong&gt;&lt;em&gt;MIT Technology Review&lt;/em&gt;&amp;nbsp;Explains: Let our writers untangle the complex, messy world of technology to help you understand what’s coming next. You can read&amp;nbsp;more from the series here&lt;em&gt;.&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind the drugs Mounjaro and Zepbound, became the first healthcare company in the world to achieve a &lt;em&gt;trillion-dollar&lt;/em&gt; valuation.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_3"&gt; &lt;p&gt;Those two drugs, which are prescribed for diabetes and obesity respectively, are&amp;nbsp;generating billions of dollars in revenue for the company. Other GLP-1 agonist drugs—a class that includes Mounjaro and Zepbound, which have the same active ingredient—have also been approved to&amp;nbsp;reduce the risk of heart attack and stroke in overweight people. Many hope these apparent wonder drugs will also treat neurological disorders and potentially substance use disorders, too.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_5"&gt; &lt;p&gt;But this week we also learned that, disappointingly,&amp;nbsp;GLP-1 drugs don’t seem to help people with Alzheimer’s disease. And that people who stop taking the drugs when they become pregnant can experience potentially dangerous levels of weight gain during their pregnancies. On top of that, some researchers worry that people are using the drugs postpartum to lose pregnancy weight without understanding potential risks.&lt;/p&gt; 
 &lt;p&gt;All of this news should serve as a reminder that there’s a lot we still don’t know about these drugs. This week, let’s look at the enduring questions surrounding GLP-1 agonist drugs.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;First a quick recap.&lt;/strong&gt; Glucagon-like peptide-1 is a hormone made in the gut that helps regulate blood sugar levels. But we’ve learned that it also appears to have effects across the body. Receptors that GLP-1 can bind to have been found in multiple organs and throughout the brain, says Daniel Drucker, an endocrinologist at the University of Toronto who has been studying the hormone for decades.&lt;/p&gt; 
 &lt;p&gt;GLP-1 agonist drugs essentially mimic the hormone’s action. Quite a few have been developed, including semaglutide, tirzepatide, liraglutide, and exenatide, which have brand names like Ozempic, Saxenda and Wegovy. Some of them are recommended for some people with diabetes.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div class="whyItMatters__container--08c53dd3bc9bd04e1e42e5f7ca641ab2"&gt;&lt;div class="whyItMatters__header--19f7f372f181cc6d4c06bc7362a44382"&gt;&lt;div class="whyItMatters__title--4af28c786a2bc93df05db111c6c30618"&gt;&lt;span class="whyItMatters__askAi--577f5fe6f54de43e37258d0f2aff4394"&gt;Ask AI&lt;/span&gt;&lt;div&gt;&lt;span class="whyItMatters__whyItMattersTitle--a3694998bb578e159bbd16690b8da390"&gt;Why it matters to you?&lt;/span&gt;&lt;span class="whyItMatters__betaBadge--9e84228b864d33d5b55479433fc91b8a"&gt;BETA&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="whyItMatters__description--e1334886c092fa469388d7a24e1e1a55"&gt;&lt;span class="initial-description"&gt;Here’s why this story might matter to you, according to AI. This is a beta feature and AI hallucinates—it might get weird&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="whyItMatters__questionContainer--ec1159210954852b9178c549600959a0"&gt;&lt;div&gt;&lt;button class="whyItMatters__actionButton--674934b6df433ac81e613372979cdb6c" type="button"&gt;Tell me why it matters&lt;/button&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_7"&gt; &lt;p&gt;But because these drugs also seem to suppress appetite, they have become hugely popular weight loss aids. And studies have found that many people who take them for diabetes or weight loss experience surprising side effects; that&amp;nbsp;their mental health improves, for example, or that&amp;nbsp;they feel less inclined to smoke or consume alcohol. Research has also found that the drugs seem to increase the growth of brain cells in lab animals.&lt;/p&gt;  &lt;p&gt;So far, so promising. But there are a few outstanding gray areas.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Are they good for our brains?&lt;/strong&gt;&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_9"&gt; &lt;p&gt;Novo Nordisk, a competitor of Eli Lilly, manufactures GLP-1 drugs Wegovy and Saxenda. The company recently trialed an oral semaglutide in people with Alzheimer’s disease who had mild cognitive impairment or mild dementia. The placebo-controlled trial included 3808 volunteers.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_11"&gt; &lt;p&gt;Unfortunately, the company found that the drug did not appear to delay the progression of Alzheimer’s disease in the volunteers who took it.&lt;/p&gt;  &lt;p&gt;The news came as a huge disappointment to the research community. “It was kind of crushing,” says Drucker. That’s despite the fact that, deep down, he wasn’t expecting a “clear win.” Alzheimer’s disease has proven notoriously difficult to treat, and by the time people get a diagnosis, a lot of damage has already taken place.&lt;/p&gt;  &lt;p&gt;But he is one of many that isn’t giving up hope entirely. After all, research suggests that GLP-1 reduces inflammation in the brain and improves the health of neurons, and that it appears to improve the way brain regions communicate with each other. This all implies that GLP-1 drugs should benefit the brain, says Drucker. There’s still a chance that the drugs might help stave off Alzheimer’s in those who are still cognitively healthy.&lt;/p&gt; 

 &lt;p&gt;&lt;strong&gt;Are they safe before, during or after pregnancy?&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Other research published this week raises questions about the effects of GLP-1s taken around the time of pregnancy. At the moment, people are advised to plan to stop taking the medicines two months before they become pregnant. That’s partly because some animal studies suggest the drugs can harm the development of a fetus, but mainly because scientists haven’t studied the impact on pregnancy in humans.&lt;/p&gt;  &lt;p&gt;Among the broader population, research suggests that many people who take GLP-1s for weight loss&amp;nbsp;regain much of their lost weight once they stop taking those drugs. So perhaps it’s not surprising that&amp;nbsp;a study published in &lt;em&gt;JAMA&lt;/em&gt; earlier this week saw a similar effect in pregnant people.&lt;/p&gt;  &lt;p&gt;The study found that people who had been taking those drugs gained around 3.3kg more than others who had not. And those who had been taking the drugs also appeared to have a slightly higher risk of gestational diabetes, blood pressure disorders and even preterm birth.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_14"&gt; &lt;p&gt;It sounds pretty worrying. But&amp;nbsp;a different study published in August had the &lt;em&gt;opposite &lt;/em&gt;finding—it noted a reduction in the risk of those outcomes among women who had taken the drugs before becoming pregnant.&lt;/p&gt;  &lt;p&gt;If you’re wondering how to make sense of all this, you’re not the only one. No one really knows how these drugs should be used before pregnancy—or during it for that matter.&lt;/p&gt;  &lt;p&gt;Another&amp;nbsp;study out this week found that people (in Denmark) are increasingly taking GLP-1s postpartum to lose weight gained during pregnancy. Drucker tells me that, anecdotally, he gets asked about this potential use a lot.&lt;/p&gt;  &lt;p&gt;But there’s a lot going on in a postpartum body. It’s a time of huge physical and hormonal change that can include bonding, breastfeeding and even a rewiring of the brain. We have no idea if, or how, GLP-1s might affect any of those.&lt;/p&gt; 
 &lt;p&gt;&lt;strong&gt;How&lt;/strong&gt;—&lt;strong&gt;and when&lt;/strong&gt;—&lt;strong&gt;can people safely stop using them?&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Yet&amp;nbsp;another study out this week—you can tell GLP-1s are one of the hottest topics in medicine right now—looked at what happens when people stop taking tirzepatide (marketed as Zepbound) for their obesity.&lt;/p&gt; 
 &lt;p&gt;The trial participants all took the drug for 36 weeks, at which point half continued with the drug, and half were switched to a placebo for another 52 weeks. During that first 36 weeks, the weight and heart health of the participants improved.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_16"&gt; &lt;p&gt;But by the end of the study, most of those that had switched to a placebo had regained more than 25% of the weight they had originally lost. One in four had regained more than 75% of that weight, and 9% ended up at a higher weight than when they’d started the study. Their heart health also worsened.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_18"&gt;&lt;p&gt;Does that mean that people need to take these drugs forever? Scientists don’t have the answer to that one, either. Or if taking the drugs indefinitely is safe. The answer might depend on the individual, their age or health status, or what they are using the drug for.&lt;/p&gt;  &lt;p&gt;There are other gray areas. GLP-1s look promising for substance use disorders, but we don’t yet know how effective they might be. We don’t know the long-term effects these drugs have on children who take them. And we don’t know the long-term consequences these drugs might have for healthy-weight people who take them for weight loss.&lt;/p&gt;  &lt;p&gt;Earlier this year, Drucker accepted a Breakthrough Prize in Life Sciences at&amp;nbsp;a glitzy event in California. “All of these Hollywood celebrities were coming up to me and saying ‘thank you so much,’” he says. “A lot of these people don’t need to be on these medicines.”&lt;/p&gt;  &lt;p&gt;&lt;em&gt;This article first appeared in The Checkup,&amp;nbsp;&lt;/em&gt;MIT Technology Review’s&lt;em&gt;&amp;nbsp;weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first,&amp;nbsp;&lt;/em&gt;&lt;em&gt;sign up here&lt;/em&gt;.&lt;svg class="monogramTLogo" viewBox="0 0 1091.84 1091.84" xmlns="http://www.w3.org/2000/svg"&gt;&lt;polygon fill="#6d6e71" points="363.95 0 363.95 1091.84 727.89 1091.84 727.89 363.95 363.95 0"&gt;&lt;polygon fill="#939598" points="363.95 0 728.24 365.18 1091.84 364.13 1091.84 0 363.95 0"&gt;&lt;polygon fill="#414042" points="0 0 0 0.03 0 363.95 363.95 363.95 363.95 0 0 0"&gt;&lt;/svg&gt; &lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</description><content:encoded>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://wp.technologyreview.com/wp-content/uploads/2025/11/glp1-pregnancy.jpg?resize=1200,600" /&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="class"&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 chronoton/executive-summary_0"&gt;&lt;div class="chronotonExecutiveSummary__summaryContainer--3bc10da0658ecd8e2ef22c6023461fb5"&gt;&lt;button class="chronotonExecutiveSummary__toggleButton--1cd6118db37e8a8252fc4cd8bbadcb85" type="button"&gt;&lt;span class="chronotonExecutiveSummary__toggleText--a713e14989fe65c5162db2b69cb422c9"&gt;EXECUTIVE SUMMARY&lt;/span&gt;&lt;svg class="chronotonExecutiveSummary__toggleArrow--a8c1be9c06a9f066a767b3af80d859a1" fill="none" height="7" viewBox="0 0 11 7" width="11" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M1 1L5.5 5.5L10 1" stroke="#58C0B3" stroke-linecap="round" stroke-width="1.5"&gt;&lt;/svg&gt;&lt;/button&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_1 html_first"&gt; &lt;p&gt;&lt;strong&gt;&lt;em&gt;MIT Technology Review&lt;/em&gt;&amp;nbsp;Explains: Let our writers untangle the complex, messy world of technology to help you understand what’s coming next. You can read&amp;nbsp;more from the series here&lt;em&gt;.&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind the drugs Mounjaro and Zepbound, became the first healthcare company in the world to achieve a &lt;em&gt;trillion-dollar&lt;/em&gt; valuation.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_3"&gt; &lt;p&gt;Those two drugs, which are prescribed for diabetes and obesity respectively, are&amp;nbsp;generating billions of dollars in revenue for the company. Other GLP-1 agonist drugs—a class that includes Mounjaro and Zepbound, which have the same active ingredient—have also been approved to&amp;nbsp;reduce the risk of heart attack and stroke in overweight people. Many hope these apparent wonder drugs will also treat neurological disorders and potentially substance use disorders, too.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_5"&gt; &lt;p&gt;But this week we also learned that, disappointingly,&amp;nbsp;GLP-1 drugs don’t seem to help people with Alzheimer’s disease. And that people who stop taking the drugs when they become pregnant can experience potentially dangerous levels of weight gain during their pregnancies. On top of that, some researchers worry that people are using the drugs postpartum to lose pregnancy weight without understanding potential risks.&lt;/p&gt; 
 &lt;p&gt;All of this news should serve as a reminder that there’s a lot we still don’t know about these drugs. This week, let’s look at the enduring questions surrounding GLP-1 agonist drugs.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;First a quick recap.&lt;/strong&gt; Glucagon-like peptide-1 is a hormone made in the gut that helps regulate blood sugar levels. But we’ve learned that it also appears to have effects across the body. Receptors that GLP-1 can bind to have been found in multiple organs and throughout the brain, says Daniel Drucker, an endocrinologist at the University of Toronto who has been studying the hormone for decades.&lt;/p&gt; 
 &lt;p&gt;GLP-1 agonist drugs essentially mimic the hormone’s action. Quite a few have been developed, including semaglutide, tirzepatide, liraglutide, and exenatide, which have brand names like Ozempic, Saxenda and Wegovy. Some of them are recommended for some people with diabetes.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div class="whyItMatters__container--08c53dd3bc9bd04e1e42e5f7ca641ab2"&gt;&lt;div class="whyItMatters__header--19f7f372f181cc6d4c06bc7362a44382"&gt;&lt;div class="whyItMatters__title--4af28c786a2bc93df05db111c6c30618"&gt;&lt;span class="whyItMatters__askAi--577f5fe6f54de43e37258d0f2aff4394"&gt;Ask AI&lt;/span&gt;&lt;div&gt;&lt;span class="whyItMatters__whyItMattersTitle--a3694998bb578e159bbd16690b8da390"&gt;Why it matters to you?&lt;/span&gt;&lt;span class="whyItMatters__betaBadge--9e84228b864d33d5b55479433fc91b8a"&gt;BETA&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="whyItMatters__description--e1334886c092fa469388d7a24e1e1a55"&gt;&lt;span class="initial-description"&gt;Here’s why this story might matter to you, according to AI. This is a beta feature and AI hallucinates—it might get weird&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="whyItMatters__questionContainer--ec1159210954852b9178c549600959a0"&gt;&lt;div&gt;&lt;button class="whyItMatters__actionButton--674934b6df433ac81e613372979cdb6c" type="button"&gt;Tell me why it matters&lt;/button&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_7"&gt; &lt;p&gt;But because these drugs also seem to suppress appetite, they have become hugely popular weight loss aids. And studies have found that many people who take them for diabetes or weight loss experience surprising side effects; that&amp;nbsp;their mental health improves, for example, or that&amp;nbsp;they feel less inclined to smoke or consume alcohol. Research has also found that the drugs seem to increase the growth of brain cells in lab animals.&lt;/p&gt;  &lt;p&gt;So far, so promising. But there are a few outstanding gray areas.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Are they good for our brains?&lt;/strong&gt;&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_9"&gt; &lt;p&gt;Novo Nordisk, a competitor of Eli Lilly, manufactures GLP-1 drugs Wegovy and Saxenda. The company recently trialed an oral semaglutide in people with Alzheimer’s disease who had mild cognitive impairment or mild dementia. The placebo-controlled trial included 3808 volunteers.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_11"&gt; &lt;p&gt;Unfortunately, the company found that the drug did not appear to delay the progression of Alzheimer’s disease in the volunteers who took it.&lt;/p&gt;  &lt;p&gt;The news came as a huge disappointment to the research community. “It was kind of crushing,” says Drucker. That’s despite the fact that, deep down, he wasn’t expecting a “clear win.” Alzheimer’s disease has proven notoriously difficult to treat, and by the time people get a diagnosis, a lot of damage has already taken place.&lt;/p&gt;  &lt;p&gt;But he is one of many that isn’t giving up hope entirely. After all, research suggests that GLP-1 reduces inflammation in the brain and improves the health of neurons, and that it appears to improve the way brain regions communicate with each other. This all implies that GLP-1 drugs should benefit the brain, says Drucker. There’s still a chance that the drugs might help stave off Alzheimer’s in those who are still cognitively healthy.&lt;/p&gt; 

 &lt;p&gt;&lt;strong&gt;Are they safe before, during or after pregnancy?&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Other research published this week raises questions about the effects of GLP-1s taken around the time of pregnancy. At the moment, people are advised to plan to stop taking the medicines two months before they become pregnant. That’s partly because some animal studies suggest the drugs can harm the development of a fetus, but mainly because scientists haven’t studied the impact on pregnancy in humans.&lt;/p&gt;  &lt;p&gt;Among the broader population, research suggests that many people who take GLP-1s for weight loss&amp;nbsp;regain much of their lost weight once they stop taking those drugs. So perhaps it’s not surprising that&amp;nbsp;a study published in &lt;em&gt;JAMA&lt;/em&gt; earlier this week saw a similar effect in pregnant people.&lt;/p&gt;  &lt;p&gt;The study found that people who had been taking those drugs gained around 3.3kg more than others who had not. And those who had been taking the drugs also appeared to have a slightly higher risk of gestational diabetes, blood pressure disorders and even preterm birth.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_14"&gt; &lt;p&gt;It sounds pretty worrying. But&amp;nbsp;a different study published in August had the &lt;em&gt;opposite &lt;/em&gt;finding—it noted a reduction in the risk of those outcomes among women who had taken the drugs before becoming pregnant.&lt;/p&gt;  &lt;p&gt;If you’re wondering how to make sense of all this, you’re not the only one. No one really knows how these drugs should be used before pregnancy—or during it for that matter.&lt;/p&gt;  &lt;p&gt;Another&amp;nbsp;study out this week found that people (in Denmark) are increasingly taking GLP-1s postpartum to lose weight gained during pregnancy. Drucker tells me that, anecdotally, he gets asked about this potential use a lot.&lt;/p&gt;  &lt;p&gt;But there’s a lot going on in a postpartum body. It’s a time of huge physical and hormonal change that can include bonding, breastfeeding and even a rewiring of the brain. We have no idea if, or how, GLP-1s might affect any of those.&lt;/p&gt; 
 &lt;p&gt;&lt;strong&gt;How&lt;/strong&gt;—&lt;strong&gt;and when&lt;/strong&gt;—&lt;strong&gt;can people safely stop using them?&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Yet&amp;nbsp;another study out this week—you can tell GLP-1s are one of the hottest topics in medicine right now—looked at what happens when people stop taking tirzepatide (marketed as Zepbound) for their obesity.&lt;/p&gt; 
 &lt;p&gt;The trial participants all took the drug for 36 weeks, at which point half continued with the drug, and half were switched to a placebo for another 52 weeks. During that first 36 weeks, the weight and heart health of the participants improved.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;aside class="related__wrap"&gt;&lt;/aside&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_16"&gt; &lt;p&gt;But by the end of the study, most of those that had switched to a placebo had regained more than 25% of the weight they had originally lost. One in four had regained more than 75% of that weight, and 9% ended up at a higher weight than when they’d started the study. Their heart health also worsened.&lt;/p&gt; &lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class="gutenbergContent__content--109b03a769a11e8ae3acbab352a64269 html_18"&gt;&lt;p&gt;Does that mean that people need to take these drugs forever? Scientists don’t have the answer to that one, either. Or if taking the drugs indefinitely is safe. The answer might depend on the individual, their age or health status, or what they are using the drug for.&lt;/p&gt;  &lt;p&gt;There are other gray areas. GLP-1s look promising for substance use disorders, but we don’t yet know how effective they might be. We don’t know the long-term effects these drugs have on children who take them. And we don’t know the long-term consequences these drugs might have for healthy-weight people who take them for weight loss.&lt;/p&gt;  &lt;p&gt;Earlier this year, Drucker accepted a Breakthrough Prize in Life Sciences at&amp;nbsp;a glitzy event in California. “All of these Hollywood celebrities were coming up to me and saying ‘thank you so much,’” he says. “A lot of these people don’t need to be on these medicines.”&lt;/p&gt;  &lt;p&gt;&lt;em&gt;This article first appeared in The Checkup,&amp;nbsp;&lt;/em&gt;MIT Technology Review’s&lt;em&gt;&amp;nbsp;weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first,&amp;nbsp;&lt;/em&gt;&lt;em&gt;sign up here&lt;/em&gt;.&lt;svg class="monogramTLogo" viewBox="0 0 1091.84 1091.84" xmlns="http://www.w3.org/2000/svg"&gt;&lt;polygon fill="#6d6e71" points="363.95 0 363.95 1091.84 727.89 1091.84 727.89 363.95 363.95 0"&gt;&lt;polygon fill="#939598" points="363.95 0 728.24 365.18 1091.84 364.13 1091.84 0 363.95 0"&gt;&lt;polygon fill="#414042" points="0 0 0 0.03 0 363.95 363.95 363.95 363.95 0 0 0"&gt;&lt;/svg&gt; &lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</content:encoded><guid isPermaLink="false">https://www.technologyreview.com/2025/11/28/1128511/what-we-still-dont-know-about-weight-loss-drugs/</guid><pubDate>Fri, 28 Nov 2025 10:00:00 +0000</pubDate></item><item><title>[NEW] How background AI builds operational resilience &amp; visible ROI (AI News)</title><link>https://www.artificialintelligence-news.com/news/how-background-ai-builds-operational-resilience-visible-roi/</link><description>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://www.artificialintelligence-news.com/wp-content/uploads/2025/11/Picture1-1.jpg" /&gt;&lt;/div&gt;&lt;p&gt;If you asked most enterprise leaders which AI tools are delivering ROI, many would point to front-end chatbots or customer support automation. That’s the wrong door. The most value-generating AI systems today aren’t loud, customer-facing marvels. They’re tucked away in backend operations. They work silently, flagging irregularities in real-time, automating risk reviews, mapping data lineage, or helping compliance teams detect anomalies before regulators do. The tools don’t ask for credit, but are saving millions.&lt;/p&gt;&lt;p&gt;Operational resilience no longer comes from having the loudest AI tool. It comes from having the smartest one, placed where it quietly does the work of five teams before lunch.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-the-machines-that-spot-what-humans-don-t"&gt;The machines that spot what humans don’t&lt;/h3&gt;&lt;p&gt;Take the case of a global logistics company that integrated a background AI system for monitoring procurement contracts. The tool scanned thousands of PDFs, email chains, and invoice patterns per hour. No flashy dashboard. No alerts that interrupt workflow. Just continuous monitoring. In the first six months, it flagged multiple vendor inconsistencies that, if left unchecked, would have resulted in regulatory audits.&lt;/p&gt;&lt;p&gt;The system didn’t just detect anomalies. It interpreted patterns. It noticed a vendor whose delivery timelines were always one day off compared to logged timestamps. Humans had seen those reports for months. But the AI noticed that the error always occurred near quarter-end. The conclusion? Inventory padding. That insight led to a contract renegotiation that saved millions.&lt;/p&gt;&lt;p&gt;This isn’t hypothetical. One similar real-world use case reported a seven-figure operational loss prevented through a near-identical approach. That’s the kind of ROI that doesn’t need a flashy pitch deck.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-why-advanced-education-still-matters-in-the-age-of-ai"&gt;Why advanced education still matters in the age of AI&lt;/h3&gt;&lt;p&gt;It’s easy to fall into the trap of thinking AI tools are replacing human expertise. But smart organisations aren’t replacing but reinforcing. People with advanced academic backgrounds are helping enterprises integrate AI with strategic precision.&lt;/p&gt;&lt;p&gt;Specifically, those with a doctorate of business administration in business intelligence bring an irreplaceable level of systems thinking and contextual insight. The professionals understand the complexity behind data ecosystems, from governance models to algorithmic biases, and can assess which tools serve long-term resilience versus short-term automation hype.&lt;/p&gt;&lt;p&gt;When AI models are trained on historical data, it takes educated leadership to spot where historical bias may become a future liability. And when AI starts making high-stakes decisions, you need someone who can ask better questions about risk exposure, model explainability, and ethics in decision-making. This is where doctorates aren’t just nice to have – they’re essential.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-invisible-doesn-t-mean-simple"&gt;Invisible doesn’t mean simple&lt;/h3&gt;&lt;p&gt;Too often, companies install AI as if it were antivirus software. Set it, forget it, hope it works. That’s how you get black-box risk. Invisible tools must still be transparent internally. It’s not enough to say, “AI flagged it.” The teams relying on these tools – risk officers, auditors, operations leads – must understand the decision-making logic or at least the signals that drive the alert. The requires not just technical documentation, but collaboration between engineers and business units.&lt;/p&gt;&lt;p&gt;Enterprises that win with background AI systems build what could be called “decision-ready infrastructure.” The are workflows where data ingestion, validation, risk detection, and notification are all stitched together. Not in silos. Not in parallel systems. But in one loop that feeds actionable insight straight to the team responsible. That’s resilience.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-where-operational-ai-works-best"&gt;Where operational AI works best&lt;/h3&gt;&lt;p&gt;Here’s where invisible AI is already proving its worth in industries:&lt;/p&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Compliance Monitoring: Automatically detecting early signs of non-compliance in internal logs, transactional data, and communication channels without triggering false positives.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Data Integrity: Identifying stale, duplicate, or inconsistent data in business units to prevent decision errors and reporting flaws.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Fraud Detection: Recognising pattern shifts in transactions before losses occur. Not reactive alerts after the fact.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Supply Chain Optimisation: Mapping supplier dependencies and predicting bottlenecks based on third-party risk signals or external disruptions.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;In all these cases, the key isn’t automation for automation’s sake. It’s precision. AI models that are well-calibrated, integrated with domain knowledge, and fine-tuned by experts – not simply deployed off the shelf.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-what-makes-the-systems-resilient"&gt;What makes the systems resilient?&lt;/h3&gt;&lt;p&gt;Operational resilience isn’t built in a sprint. It’s the result of smart layering. One layer catches data inconsistencies. Another tracks compliance drift. Another layer analyses behavioural signals in departments. And yet another feeds all of that into a risk model trained on historical issues.&lt;/p&gt;&lt;p&gt;The resilience depends on:&lt;/p&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Human supervision with domain expertise, especially from those trained in business intelligence.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Cross-functional transparency, so that audit, tech, and business teams are aligned.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;The ability to adapt models over time as the business evolves, not just retrain when performance dips.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Systems that get this wrong often create alert fatigue or over-correct with rigid rule-based models. That’s not AI. That’s bureaucracy in disguise.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-real-roi-doesn-t-scream"&gt;Real ROI doesn’t scream&lt;/h3&gt;&lt;p&gt;Most ROI-focused teams chase visibility. Dashboards, reports, charts. But the most valuable AI tools don’t scream. They tap a shoulder. They point out a loose thread. They suggest a second look. That’s where the money is. Quiet detection. Small interventions. Avoided disasters.&lt;/p&gt;&lt;p&gt;The companies that treat AI as a quiet partner – not a front-row magician – are already ahead. They’re using it to build internal resilience, not just customer-facing shine. They’re integrating it with human intelligence, not replacing it. And most of all, they’re measuring ROI not by how cool the tech looks, but by how quietly it works.&lt;/p&gt;&lt;p&gt;That’s the future. Invisible AI agents and assistants. Visible outcomes. Real, measurable resilience.&lt;/p&gt;</description><content:encoded>&lt;div&gt;&lt;img class="ff-og-image-inserted" src="https://www.artificialintelligence-news.com/wp-content/uploads/2025/11/Picture1-1.jpg" /&gt;&lt;/div&gt;&lt;p&gt;If you asked most enterprise leaders which AI tools are delivering ROI, many would point to front-end chatbots or customer support automation. That’s the wrong door. The most value-generating AI systems today aren’t loud, customer-facing marvels. They’re tucked away in backend operations. They work silently, flagging irregularities in real-time, automating risk reviews, mapping data lineage, or helping compliance teams detect anomalies before regulators do. The tools don’t ask for credit, but are saving millions.&lt;/p&gt;&lt;p&gt;Operational resilience no longer comes from having the loudest AI tool. It comes from having the smartest one, placed where it quietly does the work of five teams before lunch.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-the-machines-that-spot-what-humans-don-t"&gt;The machines that spot what humans don’t&lt;/h3&gt;&lt;p&gt;Take the case of a global logistics company that integrated a background AI system for monitoring procurement contracts. The tool scanned thousands of PDFs, email chains, and invoice patterns per hour. No flashy dashboard. No alerts that interrupt workflow. Just continuous monitoring. In the first six months, it flagged multiple vendor inconsistencies that, if left unchecked, would have resulted in regulatory audits.&lt;/p&gt;&lt;p&gt;The system didn’t just detect anomalies. It interpreted patterns. It noticed a vendor whose delivery timelines were always one day off compared to logged timestamps. Humans had seen those reports for months. But the AI noticed that the error always occurred near quarter-end. The conclusion? Inventory padding. That insight led to a contract renegotiation that saved millions.&lt;/p&gt;&lt;p&gt;This isn’t hypothetical. One similar real-world use case reported a seven-figure operational loss prevented through a near-identical approach. That’s the kind of ROI that doesn’t need a flashy pitch deck.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-why-advanced-education-still-matters-in-the-age-of-ai"&gt;Why advanced education still matters in the age of AI&lt;/h3&gt;&lt;p&gt;It’s easy to fall into the trap of thinking AI tools are replacing human expertise. But smart organisations aren’t replacing but reinforcing. People with advanced academic backgrounds are helping enterprises integrate AI with strategic precision.&lt;/p&gt;&lt;p&gt;Specifically, those with a doctorate of business administration in business intelligence bring an irreplaceable level of systems thinking and contextual insight. The professionals understand the complexity behind data ecosystems, from governance models to algorithmic biases, and can assess which tools serve long-term resilience versus short-term automation hype.&lt;/p&gt;&lt;p&gt;When AI models are trained on historical data, it takes educated leadership to spot where historical bias may become a future liability. And when AI starts making high-stakes decisions, you need someone who can ask better questions about risk exposure, model explainability, and ethics in decision-making. This is where doctorates aren’t just nice to have – they’re essential.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-invisible-doesn-t-mean-simple"&gt;Invisible doesn’t mean simple&lt;/h3&gt;&lt;p&gt;Too often, companies install AI as if it were antivirus software. Set it, forget it, hope it works. That’s how you get black-box risk. Invisible tools must still be transparent internally. It’s not enough to say, “AI flagged it.” The teams relying on these tools – risk officers, auditors, operations leads – must understand the decision-making logic or at least the signals that drive the alert. The requires not just technical documentation, but collaboration between engineers and business units.&lt;/p&gt;&lt;p&gt;Enterprises that win with background AI systems build what could be called “decision-ready infrastructure.” The are workflows where data ingestion, validation, risk detection, and notification are all stitched together. Not in silos. Not in parallel systems. But in one loop that feeds actionable insight straight to the team responsible. That’s resilience.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-where-operational-ai-works-best"&gt;Where operational AI works best&lt;/h3&gt;&lt;p&gt;Here’s where invisible AI is already proving its worth in industries:&lt;/p&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Compliance Monitoring: Automatically detecting early signs of non-compliance in internal logs, transactional data, and communication channels without triggering false positives.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Data Integrity: Identifying stale, duplicate, or inconsistent data in business units to prevent decision errors and reporting flaws.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Fraud Detection: Recognising pattern shifts in transactions before losses occur. Not reactive alerts after the fact.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Supply Chain Optimisation: Mapping supplier dependencies and predicting bottlenecks based on third-party risk signals or external disruptions.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;In all these cases, the key isn’t automation for automation’s sake. It’s precision. AI models that are well-calibrated, integrated with domain knowledge, and fine-tuned by experts – not simply deployed off the shelf.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-what-makes-the-systems-resilient"&gt;What makes the systems resilient?&lt;/h3&gt;&lt;p&gt;Operational resilience isn’t built in a sprint. It’s the result of smart layering. One layer catches data inconsistencies. Another tracks compliance drift. Another layer analyses behavioural signals in departments. And yet another feeds all of that into a risk model trained on historical issues.&lt;/p&gt;&lt;p&gt;The resilience depends on:&lt;/p&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Human supervision with domain expertise, especially from those trained in business intelligence.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;Cross-functional transparency, so that audit, tech, and business teams are aligned.&lt;/li&gt;&lt;/ul&gt;&lt;ul class="wp-block-list"&gt;&lt;li&gt;The ability to adapt models over time as the business evolves, not just retrain when performance dips.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Systems that get this wrong often create alert fatigue or over-correct with rigid rule-based models. That’s not AI. That’s bureaucracy in disguise.&lt;/p&gt;&lt;h3 class="wp-block-heading" id="h-real-roi-doesn-t-scream"&gt;Real ROI doesn’t scream&lt;/h3&gt;&lt;p&gt;Most ROI-focused teams chase visibility. Dashboards, reports, charts. But the most valuable AI tools don’t scream. They tap a shoulder. They point out a loose thread. They suggest a second look. That’s where the money is. Quiet detection. Small interventions. Avoided disasters.&lt;/p&gt;&lt;p&gt;The companies that treat AI as a quiet partner – not a front-row magician – are already ahead. They’re using it to build internal resilience, not just customer-facing shine. They’re integrating it with human intelligence, not replacing it. And most of all, they’re measuring ROI not by how cool the tech looks, but by how quietly it works.&lt;/p&gt;&lt;p&gt;That’s the future. Invisible AI agents and assistants. Visible outcomes. Real, measurable resilience.&lt;/p&gt;</content:encoded><guid isPermaLink="false">https://www.artificialintelligence-news.com/news/how-background-ai-builds-operational-resilience-visible-roi/</guid><pubDate>Fri, 28 Nov 2025 10:51:13 +0000</pubDate></item></channel></rss>